ABO-Incompatible Liver Transplantation: State of Art and Future Perspectives.

ABO-Incompatible Liver Transplantation: State of Art and Future Perspectives. Curr Pharm Des. 2020 May 05;: Authors: Cheng CH, Lee CF, Wang YC, Wu TH, Wu TJ, Chou HS, Chan KM, Lee WC Abstract ABO-incompatible (ABO-I) liver transplantation (LT) has been limited due to the increased rate of complications, including severe cellular and antibody-mediated rejection, hepatic necrosis, hepatic artery thrombosis, and biliary complications. However, several strategies for reducing preformed anti-donor ABO antibodies and B cell desensitization have improved the outcomes of ABO-I LT. As a result, ABOI LT has become a routine procedure and is a feasible option in countries with scarce deceased-organ donation or in cases without an available compatible organ donor. In this review, we describe past and present desensitizing protocols as well as emergent therapies for depleting B cell and anti-ABO antibodies with the objective of identifying approaches that could lead to new, refined strategies for maximizing the results of ABO-I LT. PMID: 32370710 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research